Andrew Tsai
Stock Analyst at Jefferies
(0.89)
# 3,880
Out of 4,966 analysts
22
Total ratings
36.84%
Success rate
-23.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $18.20 | +92.31% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $19.76 | +51.82% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $51.76 | +35.24% | 1 | Jul 14, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $95 → $110 | $105.91 | +3.86% | 1 | Jun 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $3.28 | -23.78% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $121.28 | +64.91% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $17.58 | +53.58% | 2 | Mar 19, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $1.12 | +1,060.71% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $17.63 | +98.53% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $3.68 | +796.74% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $3.34 | +349.10% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.10 | +172.73% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $3 | $0.39 | +672.00% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.58 | +489.52% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $38.71 | -40.58% | 1 | Jun 1, 2020 |
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $18.20
Upside: +92.31%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $19.76
Upside: +51.82%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $51.76
Upside: +35.24%
Verona Pharma
Jun 11, 2025
Maintains: Buy
Price Target: $95 → $110
Current: $105.91
Upside: +3.86%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.28
Upside: -23.78%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $121.28
Upside: +64.91%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $17.58
Upside: +53.58%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $1.12
Upside: +1,060.71%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $17.63
Upside: +98.53%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.68
Upside: +796.74%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $3.34
Upside: +349.10%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.10
Upside: +172.73%
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.39
Upside: +672.00%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.58
Upside: +489.52%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $38.71
Upside: -40.58%